PART I . Overview We are an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. PH1s disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killi...
Q2 FY2026 — expected 2026-09-24
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001493152-26-013664 | EDGAR | 108K words |
| 2025-04-15 | 2024-12-31 | 0000950170-25-054278 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0000950170-24-038661 | EDGAR | — |
| 2016-03-23 | 2015-12-31 | 0001144204-16-089697 | EDGAR | — |
| 2015-02-11 | 2014-12-31 | 0001144204-15-007770 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001493152-25-022390 | EDGAR | 33K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023569 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071563 | EDGAR | — |
| 2024-11-19 | 2024-09-30 | 0000950170-24-128727 | EDGAR | — |
| 2024-08-19 | 2024-06-30 | 0000950170-24-098576 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060556 | EDGAR | — |
| 2016-05-12 | 2016-03-31 | 0001144204-16-101257 | EDGAR | — |
| 2015-11-23 | 2015-09-30 | 0001144204-15-067423 | EDGAR | — |
| 2015-08-12 | 2015-06-30 | 0001144204-15-048274 | EDGAR | — |
| 2015-05-12 | 2015-03-31 | 0001144204-15-029638 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001493152-26-010602 | EDGAR | 1K words |
| 2026-03-02 | 0001493152-26-008570 | EDGAR | — |
| 2025-12-17 | 0001493152-25-028075 | EDGAR | — |
| 2025-12-16 | 0001493152-25-027969 | EDGAR | — |
| 2025-12-08 | 0001493152-25-026533 | EDGAR | — |
| 2025-11-26 | 0001493152-25-025177 | EDGAR | — |
| 2025-10-23 | 0001493152-25-019112 | EDGAR | — |
| 2025-10-16 | 0001493152-25-018269 | EDGAR | — |
| 2025-10-15 | 0001493152-25-018091 | EDGAR | — |
| 2025-09-29 | 0001493152-25-016039 | EDGAR | — |
295 total filings indexed. 270 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001541157 |
| Ticker | AKTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
| Website | https://www.akaritx.com |
| Listed | 2012-12-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report